What is the purpose and scope of Bayer's $7.25 billion Roundup settlement currently under review in Missouri court?

The $7.25 billion settlement aims to resolve nearly all current and future U.S. Roundup-related lawsuits—approximately 65,000 claims—alleging that the weedkiller caused cancer, particularly non-Hodgkin lymphoma; it offers payouts ranging from $10,000 to $165,000 based on factors including cancer severity, age at diagnosis, and exposure setting (home or occupational), and requires court approval to take effect.

Why is this Missouri court hearing considered a 'pivotal test' for Bayer, and what are the key objections to the settlement?

The hearing is a pivotal test because it determines whether Bayer can finally resolve years of litigation that have cost it billions and weighed on its share price since the 2018 Monsanto acquisition, especially after a prior $10 billion 2020 settlement left it exposed to future claims; key objections come from some plaintiffs’ attorneys who argue the deal unfairly pushes clients into Bayer’s framework and does not offer sufficient compensation, while proponents contend it ensures timely payments amid increased litigation uncertainty following a recent Supreme Court ruling in Monsanto’s favor on warning-label adequacy.

Bayer Faces Pivotal Test of $7.25 Billion Roundup Settlement in Missouri Court

Sep 11, 2026

Bayer seeks Missouri court approval for a $7.25 billion settlement to resolve tens of thousands of Roundup cancer lawsuits, aiming to conclude years of litigation over the herbicide glyphosate.

reuters

2026-01-19

Bayer Welcomes US Supreme Court Decision to Hear Roundup Appeal

2026-02-18

Bayer Proposes $7.25B Roundup Class Settlement Deal

2026-03-05

Bayer’s $7.25 billion Roundup class settlement advances

2026-04-26

Bayer's Supreme Court Case Could Impact Thousands of Roundup Lawsuits

2026-04-28

Supreme Court hears Bayer Roundup liability case with billions at stake